Golimumab for the treatment of ulcerative colitis

被引：21

作者：

Lowenberg, Mark ^{[1
]}

de Boer, Nanne K. H. ^{[2
]}

Hoentjen, Frank ^{[3
]}

机构：

[1] Acad Med Ctr, Dept Gastroenterol & Hepatol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands

[2] Vrije Univ Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Inflammatory Bowel Dis Ctr, Nijmegen, Netherlands

来源：

CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY | 2014年 / 7卷

关键词：

ulcerative colitis; UC; antitumor necrosis factor; TNF; antibodies; golimumab;

D O I：

10.2147/CEG.S48741

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. However, a proportion of UC patients for whom therapy with antiTNF agents is indicated fail or become intolerant to treatment with infliximab or adalimumab. Hence, there remains an unmet need for novel anti-TNF agents. Golimumab (Simponi (R)), a human anti-TNF antibody that is administered by monthly subcutaneous injections, is the most recently introduced TNF blocker for the treatment of UC. Here, we will discuss recent literature on clinical efficacy and safety of golimumab induction and maintenance treatment in patients with UC. Furthermore, we will discuss the positioning of golimumab for UC in current treatment algorithms.

引用

页码：53 / 59

页数：7

共 29 条

[1]

[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603

[2]

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab [J].

Armuzzi, Alessandro ;

Pugliese, Daniela ;

Nardone, Olga Maria ;

Guidi, Luisa .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 :289-296

[3]

MEDICAL PROGRESS Ulcerative Colitis [J].

Danese, Silvio ;

Fiocchi, Claudio .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (18) :1713-1725

[4]

Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis [J].

Emery, Paul ;

Fleischmann, Roy M. ;

Moreland, Larry W. ;

Hsia, Elizabeth C. ;

Strusberg, Ingrid ;

Durez, Patrick ;

Nash, Peter ;

Amante, Eric Jason B. ;

Churchill, Melvin ;

Park, Won ;

Antonio Pons-Estel, Bernardo ;

Doyle, Mittie K. ;

Visvanathan, Sudha ;

Xu, Weichun ;

Rahman, Mahboob U. .

ARTHRITIS AND RHEUMATISM, 2009, 60 (08) :2272-2283

[5]

Hutas G, 2008, CURR OPIN MOL THER, V10, P393

[6]

Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial [J].

Inman, Robert D. ;

Davis, John C., Jr. ;

van der Heijde, Desiree ;

Dickman, Laura ;

Sieper, Joachim ;

Kim, Sung Il ;

Mack, Michael ;

Han, John ;

Visvanathan, Sudha ;

Xu, Zhenhua ;

Su, Benjamin ;

Beutler, Anna ;

Braun, Juergen .

ARTHRITIS AND RHEUMATISM, 2008, 58 (11) :3402-3412

[7]

QUALITY-OF-LIFE - A VALID AND RELIABLE MEASURE OF THERAPEUTIC EFFICACY IN THE TREATMENT OF INFLAMMATORY DOWEL DISEASE [J].

IRVINE, EJ ;

FEAGAN, B ;

ROCHON, J ;

ARCHAMBAULT, A ;

FEDORAK, RN ;

GROLL, A ;

KINNEAR, D ;

SAIBIL, F ;

MCDONALD, JWD ;

VALBERG, B ;

LAUPACIS, A ;

RIDDELL, R ;

SEATON, T ;

SOMERS, S ;

DIRKS, J ;

FEUTREN, G ;

JEEJEEBHOY, K ;

SACKETT, D ;

DANDAVINO, R ;

GHENT, CN ;

GRYNOCH, JR ;

HOLBROOK, AM ;

KIBERD, BA ;

KNETEMAN, N ;

LEVINE, M ;

MANUEL, M ;

MUIRHEAD, NN ;

SAIPHOO, CS ;

SOMERVILLE, PJ ;

CAMERON, L ;

LOCKWOOD, T ;

SEGLENIEKS, E ;

TAYLORDOLMER, K ;

CHERRY, R ;

FISHER, D ;

KIRDEIKIS, P ;

MAHACHAI, V ;

SEDENS, T ;

SHERBANIUK, R ;

THOMSON, A ;

WENSEL, R ;

CASTELLI, M ;

COLLINS, S ;

CROITORU, K ;

CROWE, S ;

DONNELLY, M ;

GOODACRE, R ;

HUNT, R ;

LUMB, B ;

ROSSMAN, R .

GASTROENTEROLOGY, 1994, 106 (02) :287-296

[8]

Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study [J].

Kavanaugh, Arthur ;

McInnes, Iain ;

Mease, Philip ;

Krueger, Gerald G. ;

Gladman, Dafna ;

Gomez-Reino, Juan ;

Papp, Kim ;

Zrubek, Julie ;

Mudivarthy, Surekha ;

Mack, Michael ;

Visvanathan, Sudha ;

Beutler, Anna .

ARTHRITIS AND RHEUMATISM, 2009, 60 (04) :976-986

[9]

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate [J].

Kay, Jonathan ;

Matteson, Eric L. ;

Dasgupta, Bhaskar ;

Nash, Peter ;

Durez, Patrick ;

Hall, Stephen ;

Hsia, Elizabeth C. ;

Han, John ;

Wagner, Carrie ;

Xu, Zhenhua ;

Visvanathan, Sudha ;

Rahman, Mahboob U. .

ARTHRITIS AND RHEUMATISM, 2008, 58 (04) :964-975

[10]

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study [J].

Keystone, E. C. ;

Genovese, M. C. ;

Klareskog, L. ;

Hsia, E. C. ;

Hall, S. T. ;

Miranda, P. C. ;

Pazdur, J. ;

Bae, S-C ;

Palmer, W. ;

Zrubek, J. ;

Wiekowski, M. ;

Visvanathan, S. ;

Wu, Z. ;

Rahman, M. U. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) :789-796

← 1 2 3 →